Evidence map›Paper›PMID 27052244›Full record

ReviewWiener klinische Wochenschrift2016

[Maturity onset diabetes of the young (MODY) - screening, diagnostic and therapy].

Susanne Kaser, Michael Resl

Abstract readReview
PubMed Publisher
In one paragraph

Review in Wiener klinische Wochenschrift, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Susanne KaserDepartment für Innere Medizin 1, Medizinische Universität Innsbruck, Innsbruck, Österreich. Susanne.Kaser@i-med.ac.at.
Michael ReslInterne Abteilung, Konventhospital der Barmherzigen Brüder Linz, Linz, Österreich.
Convent Hospital of the Brothers of Saint John of God · ATInnsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maturity onset diabetes of the young (MODY) is a group of monogenetic diabetes types affecting up to 2% all known diabetics. Transcription factor MODY (HNF1α, HNF4α), the most frequent forms of MODY, allow treatment with sulfonylureas, mutations of glucokinase (GCK-MODY) usually do not require any therapy. Especially in younger patients correct diagnosis of MODY often results in discontinuation of insulin therapy and initiation of a sulfonylurea. Accordingly, in patients with diabetes onset below age of 25 years, with a positive family history for diabetes and negative autoantibodies screening for MODY is recommended.

Indexed as

Practice Guidelines as TopicAustriaDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDrug Administration ScheduleEvidence-Based MedicineHumansHypoglycemic AgentsMass ScreeningSulfonylurea CompoundsTreatment OutcomeHypoglycemic AgentsSulfonylurea CompoundsDiabetesGlucokinase mutationMonogeneticTranscription factors

Identifiers

PMID27052244
OpenAlexW2339333864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.